- Home
- OPTN vs BEAT Comparison
OPTN vs BEAT Comparison
Compare OPTN & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPTN
- BEAT
- Stock Information
- Founded
- OPTN 2010
- BEAT 2015
- Country
- OPTN United States
- BEAT United States
- Employees
- OPTN N/A
- BEAT N/A
- Industry
- OPTN Biotechnology: Pharmaceutical Preparations
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- OPTN Health Care
- BEAT Technology
- Exchange
- OPTN Nasdaq
- BEAT Nasdaq
- Market Cap
- OPTN 92.8M
- BEAT 55.6M
- IPO Year
- OPTN 2017
- BEAT 2021
- Fundamental
- Price
- OPTN $9.39
- BEAT $1.81
- Analyst Decision
- OPTN Hold
- BEAT Buy
- Analyst Count
- OPTN 3
- BEAT 1
- Target Price
- OPTN $9.00
- BEAT $8.00
- AVG Volume (30 Days)
- OPTN 41.7K
- BEAT 55.5K
- Earning Date
- OPTN 05-20-2025
- BEAT 05-13-2025
- Dividend Yield
- OPTN N/A
- BEAT N/A
- EPS Growth
- OPTN N/A
- BEAT N/A
- EPS
- OPTN N/A
- BEAT N/A
- Revenue
- OPTN $78,226,000.00
- BEAT N/A
- Revenue This Year
- OPTN $30.49
- BEAT N/A
- Revenue Next Year
- OPTN $13.51
- BEAT N/A
- P/E Ratio
- OPTN N/A
- BEAT N/A
- Revenue Growth
- OPTN 10.20
- BEAT N/A
- 52 Week Low
- OPTN $4.82
- BEAT $1.45
- 52 Week High
- OPTN $20.03
- BEAT $3.48
- Technical
- Relative Strength Index (RSI)
- OPTN 76.15
- BEAT 49.82
- Support Level
- OPTN $9.14
- BEAT $1.78
- Resistance Level
- OPTN $9.45
- BEAT $1.91
- Average True Range (ATR)
- OPTN 0.08
- BEAT 0.15
- MACD
- OPTN -0.07
- BEAT 0.02
- Stochastic Oscillator
- OPTN 80.71
- BEAT 44.67
About OPTN OptiNose Inc.
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.